Evidence for tissue‐ and cell‐type selective activation of the vitamin D receptor by Ro‐26‐9228, a noncalcemic analog of vitamin D3
- 6 January 2003
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 88 (2) , 267-273
- https://doi.org/10.1002/jcb.10344
Abstract
Our recent studies have shown that the vitamin D analog Ro‐26‐9228 restores bone mineral density without inducing hypercalcemia in osteopenic rats. Our ex vivo experiments demonstrated that the analog upregulated gene expression in trabecular bone but not in the duodenum of female rats. We examined the mechanism for the tissue selectivity of Ro‐26‐9228 in Caco‐2, a human cell line of intestinal origin, and hFOB, and a human fetal osteoblast cell line. We found that the abilities of Ro‐26‐9228 and the natural hormone, 1,25‐dihydroxyvitamin D3 (1,25D3) to induce VDRE‐reporter gene expression in transiently transfected human osteoblasts are similar. In contrast, in Caco‐2 cells, Ro‐26‐9228 induces 40‐fold less reporter gene expression than 1,25D3 does. We also examined the abilities of the vitamin D receptor (VDR)‐ligand complexes from these two cell lines to interact with partners of transcription (glucocorticoid receptor‐interacting protein, VDR‐interacting protein, and retinoid X receptor), in pull‐down assays. These assays revealed that 1,25D3 induces similar levels of interaction of these co‐factors with VDR from both osteoblasts and intestinal cells. In contrast, Ro‐26‐9228 induces significant interaction of VDR from osteoblast cells with these co‐factors, but less of VDR from Caco‐2 cells. These results suggest that the cellular environment of intestinal cells, unlike that of osteoblasts, represses the ability of VDR‐Ro‐26‐9228 complexes to interact with transcription partners. J. Cell. Biochem. 88: 267–273, 2003.Keywords
Funding Information
- National Institute of Health (DK 50583 (to S.P.))
This publication has 39 references indexed in Scilit:
- Molecular Determinants for the Tissue Specificity of SERMsScience, 2002
- Analysis of the Molecular Mechanism for the Antagonistic Action of a Novel 1α,25-Dihydroxyvitamin D3 Analogue toward Vitamin D Receptor FunctionPublished by Elsevier ,1999
- Antagonistic Action of Novel 1α,25-Dihydroxyvitamin D3-26,23-lactone Analogs on Differentiation of Human Leukemia Cells (HL-60) Induced by 1α,25-Dihydroxyvitamin D3Published by Elsevier ,1999
- Syntheses and preventive effects of analogues related to 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (ED-71) on bone mineral loss in ovariectomized ratsBioorganic & Medicinal Chemistry, 1998
- Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized TrialJournal of Bone and Mineral Research, 1998
- Development and characterization of a conditionally immortalized human fetal osteoblastic cell lineJournal of Bone and Mineral Research, 1995
- Identification of Calbindin D-9k mRNA and Its Regulation by 1,25-Dihydroxyvitamin D3 in Caco-2 CellsArchives of Biochemistry and Biophysics, 1994
- The effect of vitamin D on rat intestinal plasma membrane Ca-pump mRNABiochemical and Biophysical Research Communications, 1991
- Photoaffinity labeling of the rat plasma vitamin D binding protein with [26,27-3H]-25-hydroxyvitamin D3-3.beta.-[N-(4-azido-2-nitrophenyl)glycinate]Biochemistry, 1986